This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Dasatinib in Relapsed or Refractory Non-Hodgkin's ...
Clinical trial

Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma

Read time: 1 mins
Last updated:26th Oct 2007
To determine the maximum tolerated dose (MTD) of Dasatinib in relapsed or refractory non-hodgkin's lymphoma (NHL) patients and to determine the safety of Dasatinib in NHL.
Category Value
Study start date 2007-10-26

View full details